Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Gan To Kagaku Ryoho ; 51(4): 433-435, 2024 Apr.
Article de Japonais | MEDLINE | ID: mdl-38644313

RÉSUMÉ

A 67-year-old man visited our hospital for epigastric pain. Esophagogastroduodenoscopy(EGD)revealed type 2 gastric cancer from the cardia to the gastric angle, and histopathological examination revealed papillary adenocarcinoma(pap), HER2-positive. Contrast-enhanced CT showed wall thickening mainly in the posterior wall of the gastric body, enlarged lymph nodes that were lumped together with the main lesion, and 8 low-absorption areas with ring shaped contrast effects in both lobes of the liver. The patient was diagnosed as gastric cancer cT4aN(+)M1[HEP], clinical Stage ⅣB. Six courses of capecitabine plus cisplatin plus trastuzumab(XP plus Tmab)therapy and 17 courses of capecitabine plus trastuzumab(X plus Tmab)therapy were performed. After chemotherapy, liver and lymph node metastases disappeared on CT and MRI. EGD showed residual gastric cancer, and the policy was to resect the primary tumor. Laparoscopic total gastrectomy with D2 lymph node dissection was performed. Pathological results showed T1b(SM)depth, no lymph node metastasis, and histologic response was Grade 2a. Six courses of X plus Tmab were administered as postoperative adjuvant chemotherapy, but were discontinued at the patient's request. Currently, 5 years have passed since the first chemotherapy and 3.5 years have passed since the surgery, and the patient is alive without recurrence, suggesting that the conversion surgery may have contributed to the prolonged survival.


Sujet(s)
Protocoles de polychimiothérapie antinéoplasique , Tumeurs du foie , Stadification tumorale , Tumeurs de l'estomac , Humains , Tumeurs de l'estomac/anatomopathologie , Tumeurs de l'estomac/traitement médicamenteux , Tumeurs de l'estomac/chirurgie , Mâle , Sujet âgé , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Tumeurs du foie/secondaire , Tumeurs du foie/traitement médicamenteux , Tumeurs du foie/chirurgie , Gastrectomie , Récidive , Facteurs temps , Capécitabine/administration et posologie , Cisplatine/administration et posologie , Trastuzumab/administration et posologie
2.
Gan To Kagaku Ryoho ; 47(9): 1367-1369, 2020 Sep.
Article de Japonais | MEDLINE | ID: mdl-33130702

RÉSUMÉ

A 51-year-old male underwent total gastrectomy for esophagogastric junction cancer(T3N0M0, Stage ⅡA). He was diagnosed with an alpha-fetoprotein(AFP) producing tumor and hepatoid adenocarcinoma. One month after radical surgery, computed tomography(CT) showed lung metastasis, and the patient's serum AFP level was high. He underwent chemotherapy( S-1 and wPTX/RAM)and eventually died 4 months after surgery.


Sujet(s)
Tumeurs du foie , Tumeurs du poumon , Tumeurs de l'estomac , Jonction oesogastrique/chirurgie , Humains , Tumeurs du poumon/traitement médicamenteux , Mâle , Adulte d'âge moyen , Tumeurs de l'estomac/traitement médicamenteux , Tumeurs de l'estomac/chirurgie , Alphafoetoprotéines
3.
Gan To Kagaku Ryoho ; 47(13): 2018-2020, 2020 Dec.
Article de Japonais | MEDLINE | ID: mdl-33468786

RÉSUMÉ

Case 1: A 51-year-old man underwent total gastrectomy for esophagogastric junction cancer. Pathological diagnosis was alpha-fetoprotein(AFP)producing cancer. One month after the surgery, lung metastasis was found on CT. Despite systemic chemotherapy, he died 4 months after the surgery. Case 2: A 79-year-old man underwent open distal gastrectomy for gastric cancer. Pathological diagnosis was AFP producing cancer. Six months after the surgery, multiple lymph node metastases were found on CT. He received chemotherapy and radiation therapy. He is currently alive 9 years 8 months after the surgery.


Sujet(s)
Tumeurs du foie , Tumeurs de l'estomac , Sujet âgé , Jonction oesogastrique , Gastrectomie , Humains , Mâle , Adulte d'âge moyen , Tumeurs de l'estomac/traitement médicamenteux , Tumeurs de l'estomac/chirurgie , Alphafoetoprotéines
4.
J Clin Biochem Nutr ; 48(2): 134-41, 2011 Mar.
Article de Anglais | MEDLINE | ID: mdl-21373266

RÉSUMÉ

Lipopolysaccharide-stimulated leukocytes secrete proinflammatory cytokines including tumor necrosis factor-α and interleukin-12. Over-activation of host defense systems may result in severe tissue damage and requires regulation. Granulocyte colony-stimulating factor and interleukin-10 are candidate cytokines for inducing tolerance to lipopolysaccharide re-stimulation. We compared cytokines secreted by lipopolysaccharide-stimulated blood cells from patients who had survived gram negative bacterial pneumonia (Pseudomonas aeruginosa, Escherichia coli or Proteus mirabilis, n = 26) and age-matched healthy volunteers (n = 18). Interleukin-12p70 and tumor necrosis factor-α expression was significantly lower in patients (p = 0.0039 and p<0.001) compared to healthy controls, while granulocyte colony-stimulating factor production was markedly higher in patients (p<0.001). Levels of interleukin-10 were comparable. Granulocyte colony-stimulating factor expression was inversely correlated with interleukin-12p70 (R = -0.71, p<0.001) and tumor necrosis factor-α (R = -0.64, p<0.001) expression; interleukin-10 showed no significant correlation. In unstimulated leukocytes from patients, cAMP levels were significantly raised (p = 0.020) and were correlated inversely with interleukin-12p70 levels (R = -0.81, p<0.001) and directly with granulocyte colony-stimulating factor (R = 0.72, p = 0.0020), matrix metalloproteinase-9 (R = 0.67, p = 0.0067) and interleukin-10 (R = 0.54, p = 0.039) levels. Our results demonstrate that granulocyte colony-stimulating factor production by lipopolysaccharide-stimulated leukocytes is a useful indicator of tolerance induction in surviving pneumonia patients and that measuring cAMP in freshly isolated leukocytes may also be clinically significant.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...